These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 26091797)
1. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice. Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797 [TBL] [Abstract][Full Text] [Related]
3. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981 [TBL] [Abstract][Full Text] [Related]
4. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281 [TBL] [Abstract][Full Text] [Related]
5. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291 [TBL] [Abstract][Full Text] [Related]
6. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Hayashi T; Chan M; Norton JT; Wu CC; Yao S; Cottam HB; Tawatao RI; Corr M; Carson DA; Daniels GA Melanoma Res; 2011 Feb; 21(1):66-75. PubMed ID: 21030882 [TBL] [Abstract][Full Text] [Related]
7. Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. Dovedi SJ; Adlard AL; Ota Y; Murata M; Sugaru E; Koga-Yamakawa E; Eguchi K; Hirose Y; Yamamoto S; Umehara H; Honeychurch J; Cheadle EJ; Hughes G; Jewsbury PJ; Wilkinson RW; Stratford IJ; Illidge TM Oncotarget; 2016 Mar; 7(13):17035-46. PubMed ID: 26959743 [TBL] [Abstract][Full Text] [Related]
8. Activation of plasmacytoid dendritic cells and B cells with two structurally different Toll-like receptor 7 agonists. Berggren O; Pucholt P; Amcoff C; Rönnblom L; Eloranta ML Scand J Immunol; 2020 Jun; 91(6):e12880. PubMed ID: 32219875 [TBL] [Abstract][Full Text] [Related]
9. TLR7 is a key regulator of innate immunity against Japanese encephalitis virus infection. Nazmi A; Mukherjee S; Kundu K; Dutta K; Mahadevan A; Shankar SK; Basu A Neurobiol Dis; 2014 Sep; 69():235-47. PubMed ID: 24909816 [TBL] [Abstract][Full Text] [Related]
10. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767 [TBL] [Abstract][Full Text] [Related]
11. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer. Zuo X; Cheng Q; Wang Z; Liu J; Lu W; Wu G; Zhu S; Liu X; Lv T; Song Y Int Immunopharmacol; 2024 Aug; 137():112478. PubMed ID: 38901243 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model. Ito H; Ando T; Arioka Y; Saito K; Seishima M Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876 [TBL] [Abstract][Full Text] [Related]
13. The early induction of suppressor of cytokine signaling 1 and the downregulation of toll-like receptors 7 and 9 induce tolerance in costimulated macrophages. Lee HJ; Kim KC; Han JA; Choi SS; Jung YJ Mol Cells; 2015 Jan; 38(1):26-32. PubMed ID: 25518931 [TBL] [Abstract][Full Text] [Related]
14. Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune system. Hayashi T; Yao S; Crain B; Chan M; Tawatao RI; Gray C; Vuong L; Lao F; Cottam HB; Carson DA; Corr M PLoS One; 2012; 7(9):e45860. PubMed ID: 23029281 [TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice. Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818 [TBL] [Abstract][Full Text] [Related]
16. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292 [TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Roh YS; Park S; Kim JW; Lim CW; Seki E; Kim B Hepatology; 2014 Jul; 60(1):237-49. PubMed ID: 24375615 [TBL] [Abstract][Full Text] [Related]
18. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice. Ito H; Ando T; Ogiso H; Arioka Y; Seishima M Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]